Mechanism Comparison
NAD⁺ / Sirtuin & PARP Cofactor vs Mitochondrial-Derived AMPK Activation
Side-by-side comparison of how nad⁺ / sirtuin & parp cofactor and mitochondrial-derived ampk activation differ in receptor target, downstream effects, evidence base, and the peptides that use each mechanism.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Supplementation of the NAD⁺ pool to support sirtuin, PARP, and mitochondrial metabolism.
Compounds using this mechanism
Mitochondrial-derived peptide that activates AMPK, improving glucose homeostasis and metabolic flexibility.
Compounds using this mechanism
Side-by-side mechanism table
| Attribute | NAD⁺ Cofactor | AMPK Activation |
|---|---|---|
| Pathway family | NAD⁺ / sirtuin / PARP / mitochondrial redox | Mitochondrial-nuclear communication / AMPK |
| Therapeutic areas | Longevity, Mitochondrial dysfunction, Age-related decline | Metabolic disease, Exercise / performance research, Longevity |
| Compounds | 1 | 1 |
| Total studies | 260 | 43 |
| Human studies | 15 | 2 |
| FDA approved | 0 | 0 |
| In clinical trials | 0 | 0 |
| Research-only | 1 | 1 |
| Avg evidence level | L3 | L2 |
| Primary downstream effects |
|
|
How each mechanism works
NAD⁺ / Sirtuin & PARP Cofactor
- 1Restores the cellular NAD⁺ pool.
- 2Provides substrate for sirtuin deacetylases (SIRT1-7).
- 3Supports PARP-dependent DNA repair.
- 4Powers redox reactions in mitochondrial oxidative phosphorylation.
- 5Modulates circadian clock proteins (BMAL1, CLOCK).
Mitochondrial-Derived AMPK Activation
- 1Is encoded within mitochondrial DNA (12S rRNA region).
- 2Released into circulation under metabolic stress.
- 3Activates AMPK in skeletal muscle, liver, and adipose tissue.
- 4Enhances glucose uptake via GLUT4 translocation.
- 5Promotes mitochondrial biogenesis through PGC-1α.
Evidence notes
NAD⁺ Cofactor
Precursors NR and NMN have pilot clinical data. Large outcome trials are limited; safety data is favorable.
AMPK Activation
Early-stage clinical trials (NCT05664867) are underway. Preclinical data is strong; human data is limited.
When each mechanism is most relevant
NAD⁺ / Sirtuin & PARP Cofactor
- Average evidence L3 across compounds using this mechanism
- No FDA-approved compounds yet — research use only
- Mechanism-driven limitations: Clinical outcome data (mortality, disease endpoints) is limited
Mitochondrial-Derived AMPK Activation
- No FDA-approved compounds yet — research use only
- Mechanism-driven limitations: Human clinical trial data is in early stages (NCT05664867 and others)
Frequently asked
What is the difference between NAD⁺ / Sirtuin & PARP Cofactor and Mitochondrial-Derived AMPK Activation?
NAD⁺ / Sirtuin & PARP Cofactor: Supplementation of the NAD⁺ pool to support sirtuin, PARP, and mitochondrial metabolism. Mitochondrial-Derived AMPK Activation: Mitochondrial-derived peptide that activates AMPK, improving glucose homeostasis and metabolic flexibility. The pathways differ in receptor target (NAD⁺ / sirtuin / PARP / mitochondrial redox vs Mitochondrial-nuclear communication / AMPK) and produce different downstream effects, even when the therapeutic end-goals overlap.
Which mechanism has more FDA-approved compounds?
NAD⁺ / Sirtuin & PARP Cofactor currently has 0 FDA-approved compound(s) out of 1 that use this mechanism. Mitochondrial-Derived AMPK Activation has 0 FDA-approved compound(s) out of 1. FDA approval reflects demonstrated efficacy and safety for a specific indication, not the intrinsic quality of the mechanism itself.
What therapeutic areas does each mechanism address?
NAD⁺ / Sirtuin & PARP Cofactor is primarily researched for longevity, mitochondrial dysfunction, age-related decline. Mitochondrial-Derived AMPK Activation is primarily researched for metabolic disease, exercise / performance research, longevity. The two overlap in at least one therapeutic area, which is why they are often compared.
Can compounds targeting NAD⁺ Cofactor and AMPK Activation be combined?
Combination protocols exist in clinical literature and some practice settings, but evidence for combined safety is generally weaker than evidence for either mechanism alone. Different mechanisms can produce complementary effects, but also additive or unpredictable adverse events. Any stacking should involve a qualified clinician familiar with both pathways.
Which mechanism has deeper clinical evidence?
Compounds acting through NAD⁺ / Sirtuin & PARP Cofactor account for 260 indexed studies (15 human). Compounds acting through Mitochondrial-Derived AMPK Activation account for 43 indexed studies (2 human). Study depth is only one component of evidence quality — trial design, replication, and endpoint clinical relevance matter more than raw counts.
Related mechanism comparisons
Mechanism hub
NAD⁺ / Sirtuin & PARP Cofactor →
Mechanism hub
Mitochondrial-Derived AMPK Activation →